
XLO
Xilio Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
High
0.719
Open
0.719
VWAP
--
Vol
112.28K
Mkt Cap
35.32M
Low
0.6813
Amount
--
EV/EBITDA(TTM)
--
Total Shares
36.91M
EV
-53.00M
EV/OCF(TTM)
-2.51
P/S(TTM)
--
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
7.40M
+213.96%
--
--
7.40M
+227%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Xilio Therapeutics, Inc. (XLO) for FY2025, with the revenue forecasts being adjusted by -46.93% over the past three months. During the same period, the stock price has changed by -9.78%.
Revenue Estimates for FY2025
Revise Downward

-46.93%
In Past 3 Month
EPS Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Down

-9.78%
In Past 3 Month
1 Analyst Rating

633.14% Upside
Wall Street analysts forecast XLO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLO is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy

633.14% Upside
Current: 0.682

Low
5.00
Averages
5.00
High
5.00

633.14% Upside
Current: 0.682

Low
5.00
Averages
5.00
High
5.00
Raymond James
Dane Leone
Buy
Maintains
$6 → $4
2024-11-08
Reason
Raymond James
Dane Leone
Price Target
$6 → $4
2024-11-08
Maintains
Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Xilio Therapeutics Inc (XLO.O) is -1.06, compared to its 5-year average forward P/E of -1.35. For a more detailed relative valuation and DCF analysis to assess Xilio Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-1.35
Current PE
-1.06
Overvalued PE
-0.19
Undervalued PE
-2.52
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
-0.19
Current EV/EBITDA
0.99
Overvalued EV/EBITDA
1.61
Undervalued EV/EBITDA
-1.98
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
1.19
Current PS
1.43
Overvalued PS
3.05
Undervalued PS
-0.67
Financials
Annual
Quarterly
FY2025Q1
2.93M
Total Revenue
FY2025Q1
YoY :
-16.25%
-13.85M
Operating Profit
FY2025Q1
YoY :
-22.89%
-13.27M
Net Income after Tax
FY2025Q1
YoY :
-70.97%
-0.18
EPS - Diluted
FY2025Q1
YoY :
-375.72%
28.96M
Free Cash Flow
FY2025Q1
100.00
Gross Profit Margin - %
FY2025Q1
N/A
FCF Margin - %
FY2025Q1
-452.73
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
72.8K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
1.8M
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
1.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
3
72.8K
USD
Months
3-6
0
0.0
USD
Months
6-9
1
1.8M
USD
Months
0-12
0
0.0
USD
Months
XLO News & Events
Events Timeline
2025-06-02 (ET)
2025-06-02
08:54:55
Xilio Therapeutics announces pricing of $50M public offering

2025-06-02
06:15:05
Xilio Therapeutics announces offering of warrants, no amount given

2025-06-01 (ET)
2025-06-01
16:22:44
Xilio Therapeutics announces updated Phase 2 data for vilastobart

Sign Up For More Events
Sign Up For More Events
News
7.5
07-28WSJBristol Myers Squibb and Bain Capital Form New Immunology Company
5.0
06-10NASDAQ.COMXilio Therapeutics Appoints Akintunde Bello, Ph.D., to Board of Directors
8.5
06-05NewsfilterXilio Therapeutics Announces Closing of $50.0 Million Public Offering
Sign Up For More News
People Also Watch

KSCP
Knightscope Inc
6.520
USD
-6.99%

CLST
Catalyst Bancorp Inc
12.310
USD
-0.57%

CGBS
Crown LNG Holdings Ltd
0
USD
-64.69%

FBIO
Fortress Biotech Inc
1.980
USD
+0.51%

CELU
Celularity Inc
3.290
USD
+11.15%

SSBI
Summit State Bank
11.800
USD
+1.06%

OPI
Office Properties Income Trust
0.263
USD
-5.41%

NVNI
Nvni Group Ltd
0.688
USD
+63.76%

LSB
LakeShore Biopharma Co Ltd
0.932
USD
-18.87%
FAQ

What is Xilio Therapeutics Inc (XLO) stock price today?
The current price of XLO is 0.682 USD — it has decreased -2.15 % in the last trading day.

What is Xilio Therapeutics Inc (XLO)'s business?

What is the price predicton of XLO Stock?

What is Xilio Therapeutics Inc (XLO)'s revenue for the last quarter?

What is Xilio Therapeutics Inc (XLO)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Xilio Therapeutics Inc (XLO)'s fundamentals?

How many employees does Xilio Therapeutics Inc (XLO). have?
